title: Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?
authors.affiliation: 1 Hospital e Maternidade Dr Christóvão da Gama, Santo André, SP, Brazil.|2 Department of Pathology, Loyola University Chicago, Maywood, IL, USA.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Ramacciotti
authors.affiliation: 2 Department of Pathology, Loyola University Chicago, Maywood, IL, USA.
authors.forename: Debra
authors.initials: D
authors.lastname: Hoppensteadt
authors.affiliation: 2 Department of Pathology, Loyola University Chicago, Maywood, IL, USA.
authors.forename: Jawed
authors.initials: J
authors.lastname: Fareed
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D001549:Benzamides; D011725:Pyridines; C543086:betrixaban